Literature DB >> 22989301

Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model.

Zheng Zhang1, Qin Pan, Xiao-Yan Duan, Qiang Liu, Guo-Yu Mo, Gui-Rong Rao, Jian-Gao Fan.   

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) overlapping with chronic hepatitis B virus (HBV) infection is undergoing a rapid increase in China. Therefore, the establishment and character of an animal model with both NAFLD and chronic HBV infection has become an urgent task.
METHODS: Mice with chronic HBV genotype B infection were established with a microinjection of oocytes. Transgenic and nontransgenic mice were then randomized into groups of NAFLD + HBV, HBV, NAFLD, and control and were treated with high-fat diets or common forage. At 8, 16, and 24 weeks, characteristics of NAFLD were evaluated by physical indices, liver function tests, glycolipid metabolism, and histopathological scoring. Viral dynamics were also analyzed by HBV-DNA and HBV-related antigens.
RESULTS: Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were expressed, and HBV-DNA was replicated in HBV transgenic mice at different stages in the serum and liver. Hepatic steatosis was only induced after exposure of the mice to high-fat diets, and no obvious pathological changes occurred in the HBV group from 8 to 24 weeks. Compared to mice with HBV alone, significant reductions in serum levels of HBV-DNA, HBsAg and HBeAg occurred in the NAFLD + HBV group after 24 weeks (all P < 0.05). Nevertheless, the NAFLD and NAFLD + HBV groups shared comparable physical and metabolic disorders and similar steatotic, inflammatory and fibrotic characteristics in the liver.
CONCLUSION: High-fat diets and transgenic operations on the HBV genotype B induced a rodent model of NAFLD overlapping with chronic HBV infection, and this model reduces the HBV viral factors but not the metabolic and histologic features.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989301     DOI: 10.1111/j.1440-1746.2012.07268.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  21 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress.

Authors:  Qichuang Liu; Maoyuan Mu; Huan Chen; Guoyuan Zhang; Yanqing Yang; Jun Chu; Ying Li; Fangwan Yang; Shide Lin
Journal:  Mol Cell Biochem       Date:  2021-05-13       Impact factor: 3.396

3.  Fatty liver checkmates hepatitis B virus.

Authors:  Gayatri Ramakrishna; Nirupma Trehanpati
Journal:  Hepatol Int       Date:  2018-10-12       Impact factor: 6.047

4.  BATF Interference Blocks Th17 Cell Differentiation and Inflammatory Response in Hepatitis B Virus Transgenic Mice.

Authors:  Long-Yan Chen; Xiao-Peng Fan; Yu-Chen Fan; Jing Zhao; Shuai Gao; Feng Li; Zhao-Xia Qi; Kai Wang
Journal:  Dig Dis Sci       Date:  2018-11-29       Impact factor: 3.199

Review 5.  Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact.

Authors:  Chu-wen Lin; Xiao-li Huang; Hai-lin Liu; Yan Wang
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

6.  Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?

Authors:  Roni Atalay; Süleyman Sayar; Fatma Gülçiçek Ayrancı; Şüheda Çakmak; İbrahim Halil Tanboğa; Levent Doğanay; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

7.  Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.

Authors:  Lung-Yi Mak; Rex Wan-Hin Hui; James Fung; Fen Liu; Danny Ka-Ho Wong; Bofei Li; Ka-Shing Cheung; Man-Fung Yuen; Wai-Kay Seto
Journal:  Hepatol Int       Date:  2021-06-21       Impact factor: 6.047

8.  Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B.

Authors:  Qin Pan; Rui-Nan Zhang; Yu-Qin Wang; Rui-Dan Zheng; Yu-Qiang Mi; Wen-Bin Liu; Feng Shen; Guang-Yu Chen; Jia-Fa Lu; Chan-Yan Zhu; Shu-Yi Zhang; Yi-Ming Chen; Wan-Lu Sun; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

9.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199

10.  Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease.

Authors:  Qi Wang; Wen Xie; Ligai Liu; Peng Wang; Calvin Q Pan
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.